MMP9 and breast carcinoma: Additionally, naringenin inhibited the growth potential of MDA-MB-231 breast cancer cells and downregulated the MMP-2 and MMP-9 expression by binding to Integrin β3, thereby blocking breast cancer cell movement and invasion [70].